Category: Press Release

Download PDF – Enrollment complete in Phase 2 portion of Phase 1/2 TiNivo trial;Next data presentation expected at 2018 Genitourinary Cancers Symposium in February 2018- – Investigator-sponsored studies of ficlatuzumab initiated in HNSCC and Pancreatic Cancer – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Dec. 7, 2017– AVEO Oncology (NASDAQ:AVEO) today announced clinical updates for two of its oncology programs: FOTIVDA® (tivozanib), the Company’s

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 20, 2017– AVEO Oncology (NASDAQ: AVEO) today announced the appointment of Nikhil Mehta, Ph.D., as Senior Vice President of Regulatory and Quality Assurance, effective November 20, 2017. In this role, Dr. Mehta will oversee all aspects of regulatory, quality and technical operations for the company’s portfolio. Dr. Mehta brings to AVEO more than 25 years of experience

Download PDF HEMEL HEMPSTEAD, England & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 15, 2017– EUSA Pharma and AVEO Oncology (NASDAQ:AVEO) today announced the first commercial launch of FOTIVDA® (tivozanib) with the initiation of product sales in Germany. In the European Union, Norway and Iceland, tivozanib is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (aRCC) and for adult patients who are vascular

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 8, 2017– AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will be presenting at the following investor conferences: A live webcast of the presentations can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 7, 2017– AVEO Oncology (NASDAQ:AVEO) today reported financial results for the third quarter ended September 30, 2017 and provided a business update. “The third quarter was a transformative period for AVEO, with the achievement of significant milestones in each of the three pillars of our global strategy for tivozanib. Notably, with the European approval of

Download PDF Oral Presentation Delivered at the 16th International Kidney Cancer Symposium CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England–(BUSINESS WIRE)–Nov. 6, 2017– AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced the presentation of promising results from the ongoing Phase 1 portion of the TiNivo study, a Phase 1/2 multicenter trial of tivozanib (FOTIVDA®) in combination with Bristol-Myers Squibb’s nivolumab (OPDIVO®), an

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 16, 2017– AVEO Oncology (NASDAQ:AVEO) today announced that results from the Phase 1 portion of the Phase 1/2 TiNivo study will be presented in an oral presentation at the 16th International Kidney Cancer Symposium, to be held November 3-4, 2017 in Miami. The TiNivo trial is a Phase 1/2 multicenter trial of FOTIVDA® (tivozanib) in combination

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 5, 2017– AVEO Oncology (NASDAQ:AVEO) today announced the completion of a pre-planned futility analysis of the Phase 3 TIVO-3 trial, the Company’s randomized, controlled, multi-center, open-label study to compare FOTIVDA® (tivozanib) to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC). Based on the results of the futility analysis, which was reviewed by

Download PDF Exercise of Option Triggers $2.0 Million Research and Development Payment to AVEO CAMBRIDGE, Mass. & HEMEL HEMPSTEAD, England–(BUSINESS WIRE)–Sep. 20, 2017– AVEO Oncology (NASDAQ:AVEO) and EUSA Pharma today announced that EUSA Pharma, under its multi-territory licensing agreement with AVEO for FOTIVDA® (tivozanib), has opted into the Phase 1/2 TiNivo study. Under terms of the agreement, EUSA may utilize data from the study for

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 13, 2017– AVEO Oncology (NASDAQ:AVEO) today announced the receipt of a $4 million research and development payment from EUSA Pharma related to the approval of FOTIVDA® (tivozanib) for the treatment of adult patients with advanced renal cell carcinoma in Europe, and a $0.5 million milestone payment from CANbridge related to manufacturing development activities for AV-203, AVEO’s clinical-stage ErbB3 (HER3)